{
 "as_of": "2026-11-06",
 "cmr": "no-cm-kg/MERK/NO0010405780",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# LYTIX BIOPHARMA ASA (Euronext Growth Oslo: NO0010405780) — research page\n\nAs of 2026-11-06 · no-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is LYTIX BIOPHARMA ASA, listed on Euronext Growth Oslo under ticker NO0010405780, with ISIN NO0010405780 and LEI 549300NXMIMRSBCDZO71. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed.\n\n## The disclosure read\n\nThe record holds 48 filings in the twelve months to 2026-11-06, across 39 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-06 and is of type NON-REGULATORY PRESS RELEASES, so 0 days separate it from the record date. On Euronext Growth Oslo the median is 38 filings, a median cadence gap of 7 days and a median latency of 4 days, across 85 issuers. The sector median is not on the record.\n\n## Auditor\n\nThe auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed.\n\n## Orderability\n\nThe outcome is not determinable for this issuer. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/no/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names 3 research houses from the issuer's investor-relations page: DNB Carnegie, Redeye Equity Research and Redeye.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.\n\n## Sources\n\n6 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.no-cm-kg.ai/events/MERK/NO0010405780 (the disclosure lines)\n- https://no.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.lytixbiopharma.com/investors/analyst-coverage (coverage)\n- https://mcp.no-cm-kg.ai/record/MERK/NO0010405780 (the record)\n",
 "market": "NO",
 "node": "no-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the NO vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "NO",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "NO",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "NO",
    "state": "not_on_record"
   },
   "changes": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "no-cm-kg/MERK/NO0010405780",
  "coverage": {
   "count": 3,
   "houses": [
    {
     "analyst": "Klas Palin",
     "house": "DNB Carnegie",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.lytixbiopharma.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Richard Ramanius",
     "house": "Redeye Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.lytixbiopharma.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Richard Ramanius",
     "house": "Redeye",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.lytixbiopharma.com/investors/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.lytixbiopharma.com/investors/analyst-coverage",
     "result": "read: 3 of 4 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 85,
     "median_cadence_gap_days": 7,
     "median_filings": 38,
     "median_latency_days": 4,
     "name": "Euronext Growth Oslo"
    },
    "sector": {
     "market": "NO",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE": 16,
    "ANNUAL FINANCIAL REPORT": 1,
    "HALF YEAR FINANCIAL REPORT": 4,
    "INSIDE INFORMATION": 3,
    "MANAGERS’ TRANSACTION": 6,
    "NON-REGULATORY PRESS RELEASES": 15,
    "PROSPECTUS / ADMISSION DOCUMENT": 1,
    "TOTAL NUMBER OF VOTING RIGHTS AND CAPITAL": 2
   },
   "cadence_median_gap_days": 5,
   "filing_days": 39,
   "filings": 48,
   "latency_days": 0,
   "latest": [
    {
     "category": "NON-REGULATORY PRESS RELEASES",
     "date": "2026-11-06",
     "source": "https://newsweb.oslobors.no/message/685897",
     "title": "Lytix Biopharma: Invitation to the Q3 2026 Results Presentation",
     "type": "NON-REGULATORY PRESS RELEASES"
    },
    {
     "category": "NON-REGULATORY PRESS RELEASES",
     "date": "2026-11-05",
     "source": "https://newsweb.oslobors.no/message/685661",
     "title": "Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumors",
     "type": "NON-REGULATORY PRESS RELEASES"
    },
    {
     "category": "INSIDE INFORMATION",
     "date": "2026-11-03",
     "source": "https://newsweb.oslobors.no/message/685410",
     "title": "Lytix Biopharma kunngjør at ruxotemitide i kombinasjon med pembrolizumab har nådd det primære endepunktet i fase II-studien NeoLIPA i pasienter med operabelt melanom",
     "type": "INSIDE INFORMATION"
    },
    {
     "category": "INSIDE INFORMATION",
     "date": "2026-11-03",
     "source": "https://newsweb.oslobors.no/message/685409",
     "title": "Lytix Biopharma announces ruxotemitide plus pembrolizumab meets primary endpoint in Phase II NeoLIPA study in resectable melanoma",
     "type": "INSIDE INFORMATION"
    },
    {
     "category": "ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE",
     "date": "2026-10-19",
     "source": "https://newsweb.oslobors.no/message/684354",
     "title": "Financial calendar",
     "type": "ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.no-cm-kg.ai/events/MERK/NO0010405780",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "eu-sources/no/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Euronext Growth Oslo"
   },
   "isin": {
    "read_by": "eu-sources/no/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "NO0010405780"
   },
   "jurisdiction": {
    "market": "NO",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN NO0010405780)",
    "state": "sourced",
    "value": "549300NXMIMRSBCDZO71"
   },
   "name": {
    "read_by": "eu-sources/no/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "LYTIX BIOPHARMA ASA"
   },
   "sector": {
    "market": "NO",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "NO",
    "state": "not_on_record"
   },
   "segment": {
    "market": "NO",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "eu-sources/no/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "NO0010405780"
   },
   "website": {
    "market": "NO",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "NO",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "NO",
  "node": "no-cm-kg",
  "numbers_hash": "sha256:d76184d8bcc8220bf8c563e425a11519d325428fea1197b0a001e310c50b2606",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://no.eu-cm-kg.ai/book/aio.json",
    "door": "https://no.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/no/mifid-ii-product-governance/r1",
   "section": "no.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.no-cm-kg.ai/record/MERK/NO0010405780",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "note": "on the no-cm-kg register as of 2026-11-06; the node's halt flag was not read for this record",
   "read_date": "2026-11-06",
   "value": "listed"
  }
 },
 "numbers_hash": "sha256:d76184d8bcc8220bf8c563e425a11519d325428fea1197b0a001e310c50b2606",
 "path": "/no/MERK/NO0010405780",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is LYTIX BIOPHARMA ASA, listed on Euronext Growth Oslo under ticker NO0010405780, with ISIN NO0010405780 and LEI 549300NXMIMRSBCDZO71. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 48 filings in the twelve months to 2026-11-06, across 39 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-06 and is of type NON-REGULATORY PRESS RELEASES, so 0 days separate it from the record date. On Euronext Growth Oslo the median is 38 filings, a median cadence gap of 7 days and a median latency of 4 days, across 85 issuers. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable for this issuer. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/no/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names 3 research houses from the issuer's investor-relations page: DNB Carnegie, Redeye Equity Research and Redeye.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "6 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.no-cm-kg.ai/events/MERK/NO0010405780"
  },
  {
   "for": "the orderability chapter",
   "source": "https://no.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.lytixbiopharma.com/investors/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.no-cm-kg.ai/record/MERK/NO0010405780"
  }
 ],
 "title": "LYTIX BIOPHARMA ASA (NO0010405780) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}